Report cover image

Alpha 1 Lung Disease Market

Publisher Coherent Market Insights
Published Aug 23, 2023
Length 155 Pages
SKU # CMI18163480

Description

Alpha 1 Lung Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By End User, By Region (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030


Alpha 1 Lung Disease is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency of alpha-1 antitrypsin (AAT), a protein that helps protect the lungs from damage. This condition leads to the development of chronic obstructive pulmonary disease (COPD) and liver disease.

The global market for Alpha 1 Lung Disease is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the United States and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

Key Features of the Study:
  • This report provides in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030).
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • Key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim, Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Takeda Pharmaceutical, CSL Behring, Vertex Pharmaceuticals, Amgen, Sanofi, GlaxoSmithKline, Gilead Sciences, Eli Lilly, AbbVie, Johnson & Johnson, Teva Pharmaceutical, Audentes Therapeutics, and Regeneron Pharmaceuticals.
  • Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics.
  • The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market.
Detailed Segmentation:
  • Global Alpha 1 Lung Disease Market, By Disease Type
  • Alpha-1 Antitrypsin Deficiency
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Fibrosis
  • Bronchiectasis
  • Others
  • Global Alpha 1 Lung Disease Market, By Treatment Type
  • Augmentation Therapy
  • Bronchodilators
  • Corticosteroids
  • Oxygen Therapy
  • Lung Transplantation
  • Others
  • Global Alpha 1 Lung Disease Market, By Route of Administration
  • Inhalation
  • Injectable
  • Oral
  • Global Alpha 1 Lung Disease Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Alpha 1 Lung Disease Market, By End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
  • Global Alpha 1 Lung Disease Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Company Profiles:
  • AstraZeneca
  • Boehringer Ingelheim
  • Roche
  • Novartis
  • Pfizer
  • Merck
  • Bristol-Myers Squibb
  • Takeda Pharmaceutical
  • CSL Behring
  • Vertex Pharmaceuticals
  • Amgen
  • Sanofi
  • GlaxoSmithKline
  • Gilead Sciences
  • Eli Lilly
  • AbbVie
  • Johnson & Johnson
  • Teva Pharmaceutical
  • Audentes Therapeutics
  • Regeneron Pharmaceuticals

Table of Contents

155 Pages
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Disease Type
Market Snapshot, By Treatment Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By End User
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Rising prevalence of the disease
Restraints
Limited awareness about the disease among the general population
Opportunities
Technological advancements in diagnostic techniques
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Alpha 1 Lung Disease Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Alpha 1 Lung Disease Market , By Disease Type, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2018 – 2030
Segment Trends
Alpha-1 Antitrypsin Deficiency
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Chronic Obstructive Pulmonary Disease (COPD)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Pulmonary Fibrosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Bronchiectasis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Bn)
6. Global Alpha 1 Lung Disease Market , By Treatment Type, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2030 (%)
Y-o-Y Growth Analysis, 2018– 2030
Segment Trends
Augmentation Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Bronchodilators
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Oxygen Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Lung Transplantation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
7. Global Alpha 1 Lung Disease Market , By Route of Administration, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2030 (%)
Y-o-Y Growth Analysis, 2018– 2030
Segment Trends
Inhalation
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
8. Global Alpha 1 Lung Disease Market , By Distribution Channel, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2030 (%)
Y-o-Y Growth Analysis, 2018– 2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
9. Global Alpha 1 Lung Disease Market , By End User, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, 2023and 2030 (%)
Y-o-Y Growth Analysis, 2018– 2030
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Homecare
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2023-2030,(US$ Billion)
10. Global Alpha 1 Lung Disease Market , By Region, 2023-2030, (US$ Bn)
Introduction
Market Share Analysis, By Country, 2023and 2030 (%)
Y-o-Y Growth Analysis, For Country 2018 – 2030
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2023-2030,(US$ Bn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2023-2030,(US$ Bn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2023-2030,(US$ Bn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2023-2030,(US$ Bn)
Middle East & Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2023-2030,(US$ Bn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2023-2030,(US$ Bn)
11. Competitive Landscape
AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Boehringer Ingelheim
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Roche
Novartis
Pfizer
Merck
Bristol-Myers Squibb
Takeda Pharmaceutical
CSL Behring
Vertex Pharmaceuticals
Amgen
Sanofi
GlaxoSmithKline
Gilead Sciences
Eli Lilly
AbbVie
Johnson & Johnson
Teva Pharmaceutical
Audentes Therapeutics
Regeneron Pharmaceuticals
12. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on “Alpha 1 Lung Disease Market” - Global forecast to 2030

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us